TMCnet News

Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) Highlighted in Four Abstracts for Presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
[May 28, 2015]

Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) Highlighted in Four Abstracts for Presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting


The Multiple Myeloma Research Foundation (MMRF) and its affiliate organization and clinical research network, the Multiple Myeloma Research Consortium (MMRC), will be highlighted in four oral and/or poster presentations from their research and development collaborations with academia and industry at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill., May 29 - June 2, 2015. These presentations include important clinical data on combinations in the upfront patient setting and drugs with novel mechanisms of action, including:

  • Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM)
    • Abstract Number: 8510
    • Date/Time: Tuesday, June 2, 9:45 AM to 12:45 PM
    • Session Info: Lymphoma and Plasma Cell Disorders
  • A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma
    • Abstract Number: TPS8612
    • Date/Time: Sunday, May 31, 8:00 AM to 11:30 AM
    • Session Info: Lymphoma and Plasma Cell Disorders
  • Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM)
    • bstract Number: 8580
    • Date/Time: Sunday, May 31, 8:00 AM to 11:30 AM
    • Session Info: Lymphoma and Plasma Cell Disorders
  • Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM)
    • Abstract Number: 8576
    • Date/Time: Sunday, May 31, 8:00 AM to 11:30 AM
    • Session Info: Lymphoma and Plasma Cell Disorders



"The Multiple Myeloma Research Foundation is dedicated to accelerating the clinical development of next-generation myeloma treatments," said Daniel Auclair, Ph.D., Senior Vice President of Research at the MMRF. "We are developing a diverse pipeline of the most promising therapeutic agents, and commend members of the MMRC and our industry partners for their tireless efforts in helping to extend the lives of multiple myeloma patients and seeking a cure for this fatal blood cancer."

About the Multiple Myeloma Research Foundation (MMRF)


The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised $275 million since its inception and directs nearly 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator's coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.

About Multiple Myeloma (MM)

Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 26,850 adults (14,000 men and 12,760 women) in the United States will be diagnosed with MM in 2015 and an estimated 11,240 people are predicted to die from the disease. The five-year survival rate for MM is approximately 45%, versus 28% in 1998.


[ Back To TMCnet.com's Homepage ]